Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

As the healthcare landscape continues to evolve, the insulin biosimilar market is poised for substantial growth. With increasing investments in research and development and the rising emphasis on cost ...

These insulins fall into different categories, such as generic, unbranded and biosimilar. It is not easy to figure out the differences but all these alternatives have one thing in common ...

Biosimilars with slower uptake include those in the immunology landscape, filgrastim, epoetin alfa, and insulin glargine. Biosimilars that have seen the largest breakthrough in the market include ...

Since the start of 2024, Wockhardt’s stock price has almost tripled to Rs 1,233.85 per share as on November 8.

Approximately 10 percent of the global population has diabetes, and the number is growing. This company is a leading ...

Last year, drugmaker USV said it had partnered with biotech venture Biogenomics to bring out InsuQuick, the first locally-made biosimilar version of Insulin Aspart. Wockhardt is also developing ...

for the delivery of U-100 insulin to individuals with diabetes and subcutaneous biosimilar products using NuGen's InsuJetTM device and consumables. U-100 insulin is the standard and most used ...

Slow uptake speeds achieved a 26% market share by year 5 for immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars. Some strategies have emerged to favor biosimilars over ...